Figure 3. Chronic administration of escitalopram reduced β-amyloid (Aβ) plaque load.

(A) Hippocampal plaque load for both Aβ40 and Aβ42 were significantly reduced for escitalopram 2.5 mg/d and 5 mg/d, respectively (n = 8 per group). Representative images at 5× magnification. (B) Levels of insoluble Aβ40 and Aβ42 were significantly reduced in the 2.5 mg/kg escitalopram group and in the 5 mg/kg escitalopram group, respectively (n = 8 per group). All p values resulted from 2-sided statistical tests and statistical significance was set at *p < 0.05, **p < 0.01, and ***p < 0.001.